Taysha Gene Therapies, Inc.
Close on Oct 19, 2026
- Market cap
- $1.45B
- P/E (TTM)
- –
- Dividend yield
- –
About Taysha Gene Therapies
Biological Products, (No Diagnostic Substances), SIC 2836
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company that develops adeno-associated virus-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical development program is TSHA-102, an investigational gene therapy for the treatment of females with Rett syndrome caused by MECP2 loss-of-function mutations. The company focuses on developing transformative treatments to serve patients suffering from severe monogenic central nervous system disorders and their caregivers.
The company operates clinical trial programs across the United States and Canada, evaluating adolescent, adult, and pediatric participant cohorts in its ongoing studies. Taysha Gene Therapies maintains its principal executive offices in Dallas, Texas.
Summary of the business section of Taysha Gene Therapies's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Taysha Gene Therapies, Inc.
- Headquarters
- Dallas, TX
- Address
- 3000 Pegasus Park Drive, Suite 1430 75247
- Phone
- (214) 612-0000
- Employees
- 99, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Chicago, IL
Stock & identifiers
- Ticker
- TSHA
- Exchange
- Nasdaq
- IPO date
- Sep 25, 2020
- Shares outstanding
- 326M, Aug 11, 2026
- Public float
- $544.80M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1806310
- CUSIP
- 877619106
- ISIN
- US8776191061
- EIN
- 84-3199512
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Sukumar Nagendran | President and Head of R&D, Director | 936,410 |
| Sean P. Nolan | Chief Executive Officer, Director | 4,443,802 |
| Kamran Alam | CHIEF FINANCIAL OFFICER | 1,442,131 |
| Laura Sepp-Lorenzino | Director | 127,178 |
| Alison S. Long | Director | 127,178 |
| Phillip B. Donenberg | Director | 241,289 |
| John A. Stalfort III | Director | 2,060,849 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Sean Nolan | $4.10M | $18.26M | $2.12M | $311 | – |
| FY2024 Sean Nolan | $4.73M | $4.67M | $3.06M | $98 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 99 employees, all of whom were full-time.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 4, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 27, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 12, 2020 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 25, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 18, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |